Enhancing Antibody Therapeutics Through Precision Glycoengineering Antibody therapeutics, particularly monoclonal antibodies (mAbs), have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. However, the efficacy of these therapeutics can be significantly influenced by their glycosylation patterns—the addition of sugar moieties to the antibody structure. Precision glycoengineering, the targeted modification of these […]

Aligning quality improvement (QI) measures with the CDC’s 2022 Clinical Practice Guidelines for Prescribing Opioids requires a structured approach to ensure evidence-based practices are implemented effectively. Below is a step-by-step guide to acquiring clinical evidence and providing clinical leadership in this area: 1. Understand the CDC 2022 Opioid Prescribing Guidelines Key Recommendations: Familiarize yourself with the 12 […]

Ocugen’s lead product is OCU400, a gene therapy that treats retinitis pigmentosa (RP) and Leber congenital amaurosis. OCU400 is a modifier gene therapy that aims to improve vision by resetting the retina’s gene network.  How OCU400 works OCU400 delivers a functional copy of the NR2E3 gene to the retina. NR2E3 regulates functions like photoreceptor development, metabolism, and […]

Yes, nitrosamine impurities have been a significant and hot topic in the pharmaceutical industry and regulatory circles in recent years. Nitrosamines are a class of chemical compounds that can be potentially carcinogenic, and their presence in pharmaceutical products has raised serious safety concerns. Key Points of Concern: Regulatory Focus: Regulatory agencies such as the U.S. […]

The future of cannabinoid therapy, particularly in the context of targeted mitochondrial activation, is an emerging and promising area of research. Cannabinoids, the active compounds found in cannabis, have been shown to interact with the endocannabinoid system (ECS) and other cellular pathways, influencing various physiological processes. Mitochondria, often referred to as the powerhouses of the […]

For a newly approved biologic therapy for leukemia, the wording of the U.S. Prescribing Information (USPI) is critical to ensure clarity, accuracy, and compliance with FDA regulations while effectively communicating essential information to healthcare providers. Here are key strategies for the biologic manufacturer: 1. Adhere to FDA Format and Content Requirements: Follow the FDA’s Physician Labeling Rule (PLR) format, which […]

For a medical device manufacturer to self-certify EU conformity for a Class I cannabis oil vaporizer, the following documents must be prepared and made available to demonstrate compliance with the Medical Devices Regulation (MDR) 2017/745: Technical Documentation: A comprehensive set of documents that demonstrate the device’s design, manufacture, and performance, including: Device description and specifications. Intended […]

A 510(k) submission to the U.S. Food and Drug Administration (FDA) is a premarket notification required for demonstrating that a medical device is substantially equivalent to a legally marketed predicate device. The submission must be well-organized and comprehensive. Below is a typical Table of Contents (ToC) structure for a 510(k) application, including sections and subsections: 1. Cover Letter Applicant […]

The best single episode of any podcast (subscribe to 70) that I have heard this year. The episode is so good, I will probably repost this message a couple times in 2025. “In 1962, President John F. Kennedy said, “Those who make peaceful revolution impossible will make violent revolution inevitable.” It was a recognition of a […]

Parkinson’s Disease Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. Performed market assessment for some of the latest (2024) treatments for PD. (1) Produodopa—a new treatment approved by NICE for people with PD who experience movement-related symptoms. It’s delivered continuously by a small pump that’s inserted under the skin. (2) […]